phrykt

Rhythm Pharmaceuticals, Inc. (RYTM): who owns it and who trades it

As of Nov 16, 2026, RYTM insiders reported 48 open-market sales worth $36.4M and no purchases in the last 12 months, with 97% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Kayden Lee (Vice president), with $8.9M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Rhythm Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RYTM

303 funds and institutions reported RYTM shares worth $8.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 9.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.7%
BlackRock, Inc.9.0%
Baker Bros. Advisors LP8.2%
Primecap Management Co4.6%
Vanguard Portfolio Management LLC4.6%
Vanguard Capital Management LLC4.4%
JPMorgan Chase & Co3.9%
Perceptive Advisors LLC3.8%
State Street Corp3.8%
T. Rowe Price Associates3.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.6.67M9.73%$740MNo change
BlackRock, Inc.6.16M8.98%$684M-1%
Baker Bros. Advisors LP5.60M8.18%$622MNo change
Primecap Management Co3.17M4.62%$352M-7%
Vanguard Portfolio Management LLC3.14M4.58%$348M+3%
Vanguard Capital Management LLC3.01M4.39%$334M+1%
JPMorgan Chase & Co2.65M3.87%$292M–
Perceptive Advisors LLC2.59M3.77%$287M+9%
State Street Corp2.57M3.76%$286M+13%
T. Rowe Price Associates2.57M3.74%$285M+55%
Westfield Capital Management Co LP2.21M3.22%$245M+14%
Goldman Sachs Group Inc2.13M3.10%$236M+8%
Federated Hermes, Inc.1.79M2.61%$198M+39%
Polar Capital Holdings Plc1.66M2.43%$185M+3%
Geode Capital Management, LLC1.53M2.24%$170M+8%
Capital Research Global Investors1.53M2.24%$170M+37%
Citadel Advisors LLC1.26M1.84%$140M-11%
Checkpoint Capital L.P.1.19M1.73%$132M-3%
Siren, L.L.C.1.14M1.66%$126M+57%
Morgan Stanley1.11M1.62%$123M+58%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RYTM insiders reported $0 of open-market purchases and $36.4M of sales. 97% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$36.4M
48 trades, 9 people
Sales under a 10b5-1 plan
97%
Share of sale value
Latest trade
Sep 14, 2026
Filed Sep 14, 2026

Purchases and sales by month

$23.7M$23.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 14, 2026David P MeekerCEOSale plan2,300$105.19$242KForm 4
Sep 14, 2026David P MeekerCEOSale plan6,439$101.75$655KForm 4
Sep 14, 2026David P MeekerCEOSale plan30,746$102.35$3.1MForm 4
Sep 14, 2026David P MeekerCEOSale plan8,698$103.43$900KForm 4
Sep 14, 2026David P MeekerCEOSale plan1,817$104.55$190KForm 4
Aug 31, 2026Hunter C SmithCFOSale plan11,514$105.37$1.2MForm 4
Aug 31, 2026Hunter C SmithCFOSale plan23,072$104.59$2.4MForm 4
Aug 31, 2026Hunter C SmithCFOSale plan28,188$106.20$3MForm 4
Aug 13, 2026Joseph ShulmanChief Technical OfficerSale plan5,079$119.75$608KForm 4
Aug 13, 2026Alastair GarfieldChief Scientific OfficerSale plan1,556$117.08$182KForm 4
Aug 13, 2026Alastair GarfieldChief Scientific OfficerSale plan800$119.17$95.3KForm 4
Aug 13, 2026Alastair GarfieldChief Scientific OfficerSale plan2,007$116.11$233KForm 4
Aug 13, 2026Alastair GarfieldChief Scientific OfficerSale plan3,400$118.28$402KForm 4
Aug 13, 2026Jennifer Kayden LeeVice presidentSale plan75,834$117.38$8.9MForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan14,568$115.43$1.7MForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan18,208$116.49$2.1MForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan17,319$117.47$2MForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan1,000$112.86$113KForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan2,300$111.80$257KForm 4
Aug 12, 2026Yann MazabraudVice presidentSale plan3,605$114.70$413KForm 4
Jun 22, 2026Lynn A. TetraultDirectorSale plan37,000$100.32$3.7MForm 4
May 15, 2026Christopher Paul GermanCorporate Controller & CSale4,643$92.21$428KForm 4
Mar 4, 2026Christopher Paul GermanCorporate Controller & CSale5,614$89.56$503KForm 4
Feb 19, 2026Hunter C SmithCFOSale plan1,308$100.27$131KForm 4
Feb 19, 2026Hunter C SmithCFOSale plan1,692$100.92$171KForm 4
Feb 19, 2026Hunter C SmithCFOSale plan800$102.10$81.7KForm 4
Feb 19, 2026Hunter C SmithCFOSale plan585$103.28$60.4KForm 4
Feb 17, 2026Hunter C SmithCFOSale plan200$100.52$20.1KForm 4
Feb 17, 2026Hunter C SmithCFOSale plan900$101.70$91.5KForm 4
Feb 17, 2026Hunter C SmithCFOSale plan1,069$103.00$110KForm 4
Feb 17, 2026Hunter C SmithCFOSale plan1,200$99.42$119KForm 4
Feb 17, 2026Hunter C SmithCFOSale plan200$103.84$20.8KForm 4
Feb 12, 2026Hunter C SmithCFOSale plan100$100.10$10KForm 4
Feb 12, 2026Hunter C SmithCFOSale plan800$98.99$79.2KForm 4
Feb 12, 2026Hunter C SmithCFOSale plan400$97.67$39.1KForm 4
Feb 12, 2026Hunter C SmithCFOSale plan292$96.26$28.1KForm 4
Feb 11, 2026Hunter C SmithCFOSale plan2,266$98.37$223KForm 4
Feb 11, 2026Hunter C SmithCFOSale plan100$100.85$10.1KForm 4
Feb 11, 2026Hunter C SmithCFOSale plan400$99.44$39.8KForm 4
Feb 10, 2026Hunter C SmithCFOSale plan700$103.68$72.6KForm 4
Feb 10, 2026Hunter C SmithCFOSale plan100$104.76$10.5KForm 4
Feb 10, 2026Hunter C SmithCFOSale plan1,913$102.66$196KForm 4
Feb 5, 2026Hunter C SmithCFOSale plan3,381$106.06$359KForm 4
Feb 4, 2026Hunter C SmithCFOSale plan1,500$104.74$157KForm 4
Feb 4, 2026Hunter C SmithCFOSale plan747$107.67$80.4KForm 4
Feb 4, 2026Hunter C SmithCFOSale plan1,000$106.60$107KForm 4
Dec 11, 2025Pamela J. CramerChief Human Resources OfSale plan3,350$111.00$372KForm 4
Nov 20, 2025Pamela J. CramerChief Human Resources OfSale plan3,350$105.00$352KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jennifer Kayden LeeEVP, Head of North America–$8.9MAug 13, 2026
Hunter C SmithChief Financial Officer–$8.8MAug 31, 2026
Yann MazabraudEVP, Head of International–$6.6MAug 12, 2026
David P MeekerPresident and CEO, Director–$5.1MSep 14, 2026
Lynn A. TetraultDirector–$3.7MJun 22, 2026
Christopher Paul GermanCorporate Controller & CAO–$931KMay 15, 2026
Alastair GarfieldChief Scientific Officer–$913KAug 13, 2026
Pamela J. CramerChief Human Resources Officer–$724KDec 11, 2025
Joseph ShulmanChief Technical Officer–$608KAug 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RYTM short interest

High short interest. 17.0% of RYTM shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.68M RYTM shares were sold short, 17.0% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 500,502 shares, buying them all back would take about 23.3 trading days (days to cover).

Shares short, % of all shares

17.0%May 15Oct 3017.8%

Days to cover

23.3May 15Oct 3025.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.68M16.96%+6%500,50223.3
Oct 15, 202611.00M15.98%+2%816,27613.5
Sep 30, 202610.77M15.64%+5%761,70614.1
Sep 15, 202610.29M14.94%-0%512,77420.1
Aug 31, 202610.30M14.96%+1%470,67221.9
Aug 14, 202610.15M14.75%+8%829,84112.2
Jul 31, 20269.44M13.78%-1%583,68416.2
Jul 15, 20269.57M13.97%-1%696,95413.7
Jun 30, 20269.67M14.10%+21%1.28M7.6
Jun 15, 20268.01M11.68%+1%691,41811.6
May 29, 20267.91M11.54%-4%535,38814.8
May 15, 20268.28M12.09%+3%1.00M8.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Rhythm Pharmaceuticals company events

Rhythm Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026AnnouncementThe Company announced preliminary data from its ongoing Phase 2 trial evaluating RM-718 in patients with acquired hypothalamic obesity (HO), which are summarized below. Filing
  3. Jun 25, 2026VoteReported shareholder vote results. Filing
  4. Jun 15, 2026AnnouncementRhythm announced interim six-month data from its exploratory Phase 2 trial of setmelanotide in patients with PWS, which are summarized below. Filing
  5. May 5, 2026ResultsReleased financial results. Filing
  6. Apr 3, 2026LeadershipThe Board of Directors of Rhythm Pharmaceuticals, Inc. elected Kimberly J. Popovits as a non-employee director of the Company, effective on the same date. Filing
  7. Mar 26, 2026AnnouncementRhythm announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE ® (setmelanotide) to include the treatment of obesity and the control of hunger in… Filing
  8. Mar 20, 2026AnnouncementRhythm announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). Filing
  9. Mar 16, 2026AnnouncementRhythm announced the topline results from its EMANATE trial, which are summarized below. Filing
  10. Mar 2, 2026AnnouncementRhythm announced additional data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity, which are summarized below. Filing
  11. Feb 26, 2026ResultsReleased financial results. Filing
  12. Jan 9, 2026AnnouncementThe Company announced preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an increase of 11% percent on a sequential basis from the third quarter of 2025. Filing
  13. Dec 19, 2025LeadershipCamille L. Bedrosian, M.D. notified the Board of Directors of Rhythm Pharmaceuticals, Inc. of her decision to resign from the Board, effective immediately. Filing
  14. Dec 11, 2025AnnouncementRhythm announced preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), which are summarized below. ​ Rhythm enrolled 18 patients with PWS aged 6-65 years old with a BMI ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Rhythm Pharmaceuticals financials

Famous investors that hold RYTM

7 of the 50 well-known investors we track reported holding RYTM in their latest 13F filing. The largest position is Steve Cohen's, worth $69.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026726,499$69.2M0.1%+75%
Ken Griffin · Citadel AdvisorsQ3 2026316,973$30.2M0.0%-75%
Israel Englander · Millennium ManagementQ3 2026315,706$30.1M0.0%-0%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026269,900$25.7M0.6%+33%
Ken Fisher · Fisher Asset ManagementQ3 2026105,999$10.1M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202695,074$9.1M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202688,681$8.4M0.0%+30%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RYTM in the last 120 days.

FiledHolderFormStake
Oct 13, 2026JPMORGAN CHASE & CO.13G5.1%
Oct 13, 2026JPMORGAN CHASE & CO.13G5.1%

Questions about Rhythm Pharmaceuticals, Inc. (RYTM) stock

Who owns the most RYTM stock?

The largest reported owner of Rhythm Pharmaceuticals, Inc. (RYTM) is Ra Capital Management, L.P., with 9.7% of the company. In total, 303 funds and institutions reported holding RYTM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RYTM insiders buying or selling?

In the last 12 months, RYTM insiders reported no open-market purchases and 48 sales worth $36.4M. The latest trade was on Sep 14, 2026. See every trade.

What is the short interest in RYTM?

As of Oct 30, 2026, 11.68M RYTM shares were sold short, 17.0% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 500,502 shares, buying them all back would take about 23.3 trading days (days to cover). See the history.

Which famous investors hold RYTM?

7 of the 50 well-known investors we track reported RYTM in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $69.2M. See all holders.

Executive pay

Rhythm Pharmaceuticals's chief executive was paid a total of $17.5M for the year ended Dec 31, 2025, up 20% from $14.7M the year before. In the last 12 months, Rhythm Pharmaceuticals's executives and directors bought no stock on the open market and sold $36.4M.

Chief executive, total pay$17.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$54.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$5.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.